Patent classifications
C07D235/28
Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use
- Robert J. Altenbach ,
- Andrew Bogdan ,
- Sylvain Couty ,
- Nicolas Desroy ,
- Gregory A. Gfesser ,
- Christopher Gaëtan Housseman ,
- Philip R. Kym ,
- Bo Liu ,
- Thi Thu Trang Mai ,
- Karine Fabienne Malagu ,
- Nuria Merayo Merayo ,
- Olivier Laurent Picolet ,
- Mathieu Rafaël Pizzonero ,
- Xenia B. Searle ,
- Steven Emiel Van der Plas ,
- Xueqing Wang ,
- Ming C. Yeung
The invention discloses compounds of Formula (I),
##STR00001##
wherein A.sup.1, R.sup.1, R.sup.2, R.sup.3, R.sup.4, and n are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use
- Robert J. Altenbach ,
- Andrew Bogdan ,
- Sylvain Couty ,
- Nicolas Desroy ,
- Gregory A. Gfesser ,
- Christopher Gaëtan Housseman ,
- Philip R. Kym ,
- Bo Liu ,
- Thi Thu Trang Mai ,
- Karine Fabienne Malagu ,
- Nuria Merayo Merayo ,
- Olivier Laurent Picolet ,
- Mathieu Rafaël Pizzonero ,
- Xenia B. Searle ,
- Steven Emiel Van der Plas ,
- Xueqing Wang ,
- Ming C. Yeung
The invention discloses compounds of Formula (I),
##STR00001##
wherein A.sup.1, R.sup.1, R.sup.2, R.sup.3, R.sup.4, and n are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use
- Robert J. Altenbach ,
- Andrew Bogdan ,
- Sylvain Couty ,
- Nicolas Desroy ,
- Gregory A. Gfesser ,
- Christopher Gaëtan Housseman ,
- Philip R. Kym ,
- Bo Liu ,
- Thi Thu Trang Mai ,
- Karine Fabienne Malagu ,
- Nuria Merayo Merayo ,
- Olivier Laurent Picolet ,
- Mathieu Rafaël Pizzonero ,
- Xenia B. Searle ,
- Steven Emiel Van der Plas ,
- Xueqing Wang ,
- Ming C. Yeung
The invention discloses compounds of Formula (I),
##STR00001##
wherein A.sup.1, R.sup.1, R.sup.2, R.sup.3, R.sup.4, and n are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use
- Robert J. Altenbach ,
- Andrew Bogdan ,
- Sylvain Couty ,
- Nicolas Desroy ,
- Gregory A. Gfesser ,
- Christopher Gaëtan Housseman ,
- Philip R. Kym ,
- Bo Liu ,
- Thi Thu Trang Mai ,
- Karine Fabienne Malagu ,
- Nuria Merayo Merayo ,
- Olivier Laurent Picolet ,
- Mathieu Rafaël Pizzonero ,
- Xenia B. Searle ,
- Steven Emiel Van der Plas ,
- Xueqing Wang ,
- Ming C. Yeung
The invention discloses compounds of Formula (I),
##STR00001##
wherein A.sup.1, R.sup.1, R.sup.2, R.sup.3, R.sup.4, and n are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use
- Robert J. Altenbach ,
- Andrew Bogdan ,
- Sylvain Couty ,
- Nicolas Desroy ,
- Gregory A. Gfesser ,
- Christopher Gaëtan Housseman ,
- Philip R. Kym ,
- Bo Liu ,
- Thi Thu Trang Mai ,
- Karine Fabienne Malagu ,
- Nuria Merayo Merayo ,
- Olivier Laurent Picolet ,
- Mathieu Rafaël Pizzonero ,
- Xenia B. Searle ,
- Steven Emiel Van der Plas ,
- Xueqing Wang ,
- Ming C. Yeung
The invention discloses compounds of Formula (I),
##STR00001##
wherein A.sup.1, R.sup.1, R.sup.2, R.sup.3, R.sup.4, and n are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE
- Robert J. Altenbach ,
- Andrew Bogdan ,
- Sylvain Couty ,
- Nicolas Desroy ,
- Gregory A. Gfesser ,
- Christopher Gaëtan Housseman ,
- Philip R. Kym ,
- Bo Liu ,
- Thi Thu Trang Mai ,
- Karine Fabienne Malagu ,
- Nuria Merayo Merayo ,
- Olivier Laurent Picolet ,
- Mathieu Rafaël Pizzonero ,
- Xenia B. Searle ,
- Steven Emiel Van der Plas ,
- Xueqing Wang ,
- Ming C. Yeung
The invention discloses compounds of Formula (I),
##STR00001##
wherein A.sup.1, R.sup.1, R.sup.2, R.sup.3, R.sup.4, and n are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE
- Robert J. Altenbach ,
- Andrew Bogdan ,
- Sylvain Couty ,
- Nicolas Desroy ,
- Gregory A. Gfesser ,
- Christopher Gaëtan Housseman ,
- Philip R. Kym ,
- Bo Liu ,
- Thi Thu Trang Mai ,
- Karine Fabienne Malagu ,
- Nuria Merayo Merayo ,
- Olivier Laurent Picolet ,
- Mathieu Rafaël Pizzonero ,
- Xenia B. Searle ,
- Steven Emiel Van der Plas ,
- Xueqing Wang ,
- Ming C. Yeung
The invention discloses compounds of Formula (I),
##STR00001##
wherein A.sup.1, R.sup.1, R.sup.2, R.sup.3, R.sup.4, and n are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
Hindered disulfide drug conjugates
The invention relates generally to disulfide drug conjugates wherein a linker comprising a sulfur-bearing carbon atom substituted with at least one hydrocarbyl or substituted hydrocarbyl is conjugated by a disulfide bond to a cysteine sulfur atom of a targeting carrier, and wherein the linker is further conjugated to a drug moiety. The invention further relates to activated linker-drug conjugates suitable for conjugation to a targeting carrier by a disulfide bond. The invention further relates to methods for preparing hindered disulfide drug conjugates.
Ion pair catalysis of tungstate and molybdate
D The present invention relates to ion pair catalysts (I) comprising the cationic bisguanidinium ligand (A) and diperoxomolybdate anion (B). The present invention also relates to ion pair catalysts (III) comprising the cationic bisguanidinium ligand (C) and peroxotungstate anion (D). It further relates to the use of the said catalysts in the manufacture of enantiomerically enriched sulfoxides. ##STR00001##
Ion pair catalysis of tungstate and molybdate
D The present invention relates to ion pair catalysts (I) comprising the cationic bisguanidinium ligand (A) and diperoxomolybdate anion (B). The present invention also relates to ion pair catalysts (III) comprising the cationic bisguanidinium ligand (C) and peroxotungstate anion (D). It further relates to the use of the said catalysts in the manufacture of enantiomerically enriched sulfoxides. ##STR00001##